Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01361087|
Recruitment Status : Withdrawn (No outside recruitment of subjects from Main Atenolol VS Losartan NIH study)
First Posted : May 26, 2011
Last Update Posted : February 5, 2016
|Condition or disease||Intervention/treatment||Phase|
|Marfan Syndrome||Other: Blood draw||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||December 2014|
- Other: Blood draw
This study includes one blood draw to measure circulating blood levels of TGF-B.
- To determine if circulating levels of TGF-β correlate with treatment arms: Atenolol vs. Losartan. [ Time Frame: 1 year ]
- To determine if circulating levels of TGF-β correlate with clinical outcomes within a treatment group or independent treatment groups. [ Time Frame: 1 year ]These clinical outcomes may be a change in aortic root Z-score, final aortic root dimension, final aortic root Z-score and other clinical outcomes in the main Marfan trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01361087
|United States, Illinois|
|Children's Memorial Hospital Chicago|
|Chicago, Illinois, United States, 60614|